Genetic 'placebo response' marker has trial design implications, say researchers

Team discovers genetic basis for placebo response
Discovery of the genetic basis for the placebo effect in IBS patients has wider implications for protocol design and trials of personalised medicines say researchers.

Scientists from Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) claim to have identified​ genetic differences between people who respond to placebos during trials of and those who do not.

The team looked a 2003 trial (NCT00065403​) in which patients ‘treated’ with augmented placebo – combined acupuncture and physician support – showed greater reductions in symptom severity than patients in either the limited placebo group – just acupuncture – or the no treatment arm.

Analysis of blood samples taken at the time showed patients who responded most strongly had two copies of a particular version of a gene encoding catechol-O-methyltransferase (COMT), an enzyme involved in the dopamine pathway, as lead author Kathryn Hall explained.

IBS patients homozygous for the COMT val158met methionine allele were the most responsive to placebo treatment. Heterozygous patients showed an intermediate response, and homozygous valine patients showed essentially no placebo mediated symptom improvement​.”

And while the researchers admit the study was only small scale – 262 adults took part and only 122 allowed blood samples to be taken – they suggest the genetic findings have wider implications for drug research.

To our knowledge, this is the first study to demonstrate genetic modulation of true placebo effects disassociated from changes related to disease natural history and regression to the mean.

Identifying biological characteristics of placebo responders and non-responders could be key to managing underlying placebogenic factors to benefit patients by delivering personalized medicine, for example by adjusting the dose of medication in accordance to the subject's placebo susceptibility or selecting a different class of drugs for the individualized patient​.”

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more